We present a spatiotemporally integrated formulation of the optimal fractionation problem using the standard log-linear-quadratic survival model. Our objective is to choose a fluencemap and a number of fractions so as to maximize the biological effect of tumor dose averaged over its voxels subject to maximum dose, mean dose, and dose-volume constraints for various normal tissues. Constrains are expressed in biologically effective dose equivalents. We propose an efficient convex programming method to approximately solve the resulting computationally difficult model.
Introduction
In external beam radiotherapy, radiation damages both the cancer cells and the normal tissue. Thus, the goal is to maximize damage to the tumor while limiting toxic effects on nearby normal tissue. This is attempted by spatial localization and temporal dispersion of radiation dose.
Spatial localization is achieved by prescribing a high dose to the cancerous region and putting upper limits on the dose to healthy anatomies. The well-developed Intensity Modulated Raditation Therapy (IMRT) technology, the associated spatial optimization models and solution algorithms are employed to optimize the radiation intensity profile (also called the fluence-map). One standard formulation of this problem minimizes the total squared deviation from the tumor prescription dose of the doses delivered to all voxels in the tumor. This spatial side of radiation therapy has been studied extensively [8, 10, 11, 36, 46, 52, 61] .
On the temporal side, the prevalent strategy is to break the total planned dose into multiple, well-separated treatment sessions, called fractions, that are administered over several weeks. An identical dose is planned for each fraction; this is called equal-dosage fractionation. Since normal cells typically have better damage-repair capabilities than tumor cells, such temporal dispersion gives the normal tissue some time to recover between sessions. For many tumors, using a large number of fractions with a small dose in each fraction may allow the treatment planner to administer a larger total tumor dose as compared to that using a small number of fractions with a large dose in each fraction. Thus, it would seem that for these tumors, the longer the treatment course the better. However, tumors may proliferate over the treatment course, and then shorter treatment courses are believed to work better as they kill tumor cells quickly before significant proliferation. Moreover, there is an increasing interest in shorter treatment courses as they are logistically more convenient. Such tradeoffs in determining an optimal number of fractions have been clinically studied over the last several decades [1, 2, 20, 22, 27, 29, 28, 33, 39, 45, 57] . This question of choosing the number of fractions and the corresponding dose per fraction is generally referred to as the optimal fractionation problem.
The optimal number of fractions depends on the relative difference between the tumor's and the normal tissue's response to radiation as well as on the anatomy of the cancerous region with respect to the positioning of the radiation fields. The linear-quadratic (LQ) model is the prevalent framework for quantifying the tumor's and the normal tissue's response to radiation [25] . Competing fractionation schedules are thus compared using the LQ model. However, existing research on optimal fractionation that utilizes the LQ framework is limited to stylized formulations that often lead to a closed-form formula for the optimal number of fractions. This formula is derived using single-variable calculus. The idea is to maximize the biological effect (BE) of radiation dose on the tumor subject to an upper bound constraint on the biologically effective dose (BED) delivered to the normal tissue [25] . This type of literature includes [3, 4, 14, 15, 16, 17, 19, 32, 35, 42, 58] . Table  1 below summarizes the contributions of these models.
One limitation of most existing stylized models is that they only consider a single normal tissue. This not only may lead to an incorrect prediction of the number of fractions but also may yield a dose that cannot be tolerated by other nearby normal tissues that were excluded from the formulation. This important concern stems from the fact that essentially all anatomical regions of interest include multiple normal tissues. Another limitation of the stylized models is that they do not explicitly model intensity modulation and thus essentially ignore the spatial side of the problem even though IMRT technology is now ubiquitous. Such limitations curtail the practical applicability of these stylized models and thus they were addressed in our recent work in [48] .
Although, to the best of our knowledge, our model in [48] is currently the most comprehensive References ≥ 2 normal tissues closed-form for dose spatiotemporally optimal [14, 15, 16, 17, 19] No No No [3, 32] No Yes No [65] Yes No No [42] No Yes No [4, 35, 58] No Yes No [48] Yes Yes No Table 1 : A summary of some optimal fractionation models that use the LQ framework.
formulation of the optimal fractionation problem based on the LQ framework, it has an important limitation -it separated the spatial and temporal components of the problem. That is, a spatially optimized fluence-map was assumed to be available a priori and the number of fractions was then optimized with respect to this map using the concept of sparing factors. This approach simplified the optimal fractionation problem considerably -we were able to characterize the BE on tumor as a quasiconcave function of the number of fractions, which led to a simple procedure for optimizing this number. Unfortunately, this is suboptimal especially because the spatial optimization problem that is solved a priori does not directly depend on any biological dose-response parameters of the tumor or the normal tissue. Therefore, in this paper, we build a spatiotemporally integrated optimal fractionation model where the fluence-map and the number of fractions are both optimization variables. This formulation is computationally difficult to solve. We thus propose an efficient algorithm rooted in convex programming for its approximate solution. Through computer simulations on head-and-neck and prostate cancer test cases, we compare the tumor-BE achieved by this spatiotemporally integrated model with that attained by (i) a traditional IMRT fluence-map optimization model that does not optimize the number of fractions, and (ii) our spatiotemporally separated model in [48] . In our simulations, the spatiotemporally integrated approach shows 22% and 69% improvements in tumor-BE over the traditional IMRT model on an average in our head-and-neck and prostate cases, respectively. Similarly, it achieves 27% and 21% improvements in tumor-BE over the spatiotemporally separated model on an average in our head-and-neck and prostate cases, respectively. This suggests that, within the LQ framework, even approximate solution of our computationally difficult, spatiotemporally integrated model may offer some benefit over solving existing stylized models.
Problem formulation
Our overall methodology is to choose a fluence-map and a number of fractions so as to maximize the total-BE of average dose over all tumor voxels subject to constraints on normal tissue dose and on the smoothness of the fluence-map. The mathematical notation and terminology here is standard in the literature and is borrowed from our recent work in [48] .
Expression for the tumor objective function
Let n denote the number of tumor voxels, indexed by i = 1, 2, . . . , n. The radiation field is discretized into small segments called beamlets. Let k be the number of beamlets and let u ∈ k + denote the k-dimensional beamlet intensity vector used in each treatment session. Let A be the n×k, nonnegative tumor dose deposition matrix and let A i denote its ith row, which corresponds to the ith tumor voxel. That is, according to the standard linear dose deposition model [30, 53, 54, 56, 63] , A i u is the dose delivered to the ith tumor voxel andĀu n i=1 A i u n is the average dose over all tumor voxels in each session. Now consider a treatment course with N once-daily fractions. Let T double (days) denote the doubling time for the tumor and T lag (days) denote the time-lag after which tumor proliferation starts after treatment initiation. The expression [(N − 1) − T lag ] + , which is defined as max((N − 1) − T lag , 0), is the time over which the tumor proliferates. We define
and let α 0 and β 0 denote the parameters of the LQ model for the tumor. Then, according to the LQ model, the total N -session BE of the average tumor dose is given by
We wish to choose N within a clinically viable range 1 ≤ N ≤ N max and a fluence-map u to maximize (2) . This objective is nonconvex in u because we are maximizing a convex function. Fortunately, we are able to show later in Section 3 that this objective can be easily re-written in a convex (in fact, linear) form. This is achieved by observing that, when N is fixed, maximizing (2) is equivalent to maximizingĀu, a linear function. Note here that, as is common in IMRT, there are other possible choices for the objective function in this formulation. One option is to maximize the BE of the minimum tumor dose over all voxels. It turns out that, similar to our objective function, this alternative objective function can also be converted into a convex (in fact, linear) form. This is achieved by observing that, when N is fixed, maximizing the BE of the minimum tumor dose is equivalent to maximizing the minimum tumordose itself; the minimum tumor-dose can be maximized by instead maximizing a new variable t and adding a linear constraint for each tumor voxel enforcing that the dose to this voxel is at least t.
Both the average tumor-dose and the minimum tumor-dose are special cases of the well-known concept of generalized equivalent uniform dose (gEUD) [9] . This gEUD is parameterized by a single parameter p, and is given by
The gEUD can be seen as a generalized average and it is well-known that it reduces to the average tumor-dose when p = 1 and to the minimum tumor-dose as p → −∞ (see [9] ). Thus, both our approach of maximizing the BE of the average tumor-dose and the aforementioned alternative approach of maximizing the BE of the minimum tumor-dose can be seen as maximizing the BE of a particular tumor-gEUD. Consequently, both these choices of objective functions are consistent with the original motivation for the concept of EUD (see [43] ). We decided not to use the alternative maximin objective function because, as one would expect in a formulation that maximizes the worst-case BE, it led to fluence-maps that were too conservative in our preliminary numerical experiments.
Another possibility for the objective function is to maximize the average BE of the doses delivered to all tumor-voxels. This alternative, nonconvex objective is perhaps biologically more meaningful because it adds the BE over individual voxels to quantify the combined effect. Interestingly, the standard approach for solving this nonconvex problem reduces to using our objective in expression (2) . The reasoning for this is as follows. The alternative nonconvex objective function cannot be equivalently written in a convex form. The resulting optimization problem is thus computationally intractable. The standard approach for approximate solution of such problems is to instead solve a relaxation of the objective function (see, for example, the literature review in [37] ). The standard relaxation of the alternative objective is based on the fact that the sum of squares is no bigger than the square of the sum; and this relaxation of the alternative objective function yields our objective function in (2) .
We next describe our constraints in detail.
2.2 Normal tissue tolerance and fluence-map smoothness constraints 
Our model includes the three most common types of constraints on normal tissues: maximum dose constraints, mean dose constraints, and dose-volume constraints.
Maximum BED constraints for serial normal tissues
Let M 1 ⊆ M be the set of indices of serial normal tissues for which we wish to include maximum dose constraints. These are the normal tissues whose function is hampered even when a small region is damaged by radiation. Suppose, for any m ∈ M 1 , that a total dose D m max is known to be tolerated by each voxel in O m if administered in N m conv equal-dose fractions. The BED of this schedule equals BED
We use the standard approach of comparing normal tissue BED. Thus, a dose of N (A m j u) over N fractions can be tolerated by the jth voxel in normal tissue O m if
Thus, for each m ∈ M 1 , our problem formulation will include constraints (6).
Mean BED constraints for parallel normal tissues
Let M 2 ⊆ M be the set of indices of parallel normal tissues for which we wish to include mean dose constraints. These are the normal tissues where a sufficiently small portion can be damaged without affecting the organ function. Suppose, for any m ∈ M 2 , that mean dose D m mean is known to be tolerated by O m if administered in N m conv equal-dose fractions. The BED of this mean dose is given by BED
Then, for normal tissue O m , we write the mean BED constraint as
There is a subtle difference between the left hand side of this inequality and its right hand side. The left hand side quantifies the average BED of doses delivered to different voxels; the right hand side quantifies the BED of the average dose delivered to different voxels. An alternative way to express the left hand side is to use the BED of average dose. That is, to write
A m j u/n m is the average dose. However, the left hand side of our quadratic constraint (8) is biologically more meaningful than the alternative expression in (9) because it adds the BED for individual voxels to construct the combined effect. The left hand side in (8) also leads to a more conservative fluence-map because this left hand side is an upper bound on the left hand side in (9) owing to the aforementioned property about sum of squares. On the other hand, there are two benefits to using the alternative expression in (9) . The first is that it makes the left hand side consistent with the right hand side. Secondly, this alternative constraint can be equivalently expressed in terms of a linear constraint on the average dose (in Section 3, we show how to do this in the context of inequality (6), and the conversion would be identical for inequality (9)). This latter will be a computational advantage as a single linear constraint will be easier to handle than the convex quadratic constraint in (8) . Nevertheless, we decided to use the constraint in (8) for its aforementioned clinically sound foundation despite it being computationally more challenging than the linearized equivalent of constraint (9).
Dose-volume constraints for parallel normal tissues
Let M 
Since all voxels in O m have equal volume, the volume fraction is the same as the voxel fraction.
For each m ∈ M 3 and for j = 1, 2, . . . , n m , we thus define binary-valued functions f m j (N, u) as
In words, f m j (N, u) is one if the BED of dose delivered by fluence-map u to voxel j in N sessions exceeds the tolerance BED m dv ; f m j (N, u) is zero otherwise. We use the integer K m to denote n m φ m , that is, the largest integer that is at most n m φ m . Then, the dose-volume constraints are written in our optimization model as
These constraint ensure that there are at most K m voxels for which
Here, for simplicity, we have assumed that there is at most one dose-volume constraint for each normal tissue. This assumption is not needed anywhere in our algorithm and hence can be removed. In fact, we do this in our computational experiments for prostate cancer in Section 4.
Fluence-map smoothness constraints
To ensure that the intensity profile is deliverable in practice using a multi-leaf collimator, we put a smoothness constraint on each radiation field [5, 62] . In particular, for each radiation field, we bound the absolute relative difference between intensities of each pair of nearest neighbor beamlets by a fraction . Then the smoothness constraints can be written compactly in matrix format as Su ≤ 0, where S is a block diagonal matrix with entries −(1 + ), (1 − ), −1, 0, +1 at appropriate locations. We are now ready to provide our complete optimization model.
Complete optimization model
Based on the above discussion, we formulate the optimal fractionation problem as
This formulation includes all constraints that are essential for capturing the trade-off between tumor-BE and the BED for serial and parallel normal tissue. Additional constraints can also be added to this formulation if required by the treatment protocol. For instance, a minimum dose constraint on tumor could be easily added to avoid cold-spots; similarly, a maximum dose constraint on tumor could be added to increase dose-uniformity. These constraints, being linear, pose no additional computational hurdles. Moreover, these additional constraints might make our formulation more relevant for clinical practice. However, we decided not to include these constraints in the formulation for two reasons: (i) in our preliminary numerical experiments, we observed that the qualitative trends discovered in our sensitivity analyses continue to hold even when these constraints are included; and (ii) our smoothness constraints at least to some extent attempt to ensure dose-uniformity.
Observe that for each fixed N , the functions f m j (N, u) are discontinuous in u. In fact, it is well-known in the IMRT literature that dose-volume constraints are difficult to handle [46] . In realistic instances of (P ), the number of beamlets k is likely to equal a few thousand. The number of constraints can also be in the tens or hundreds of thousand depending on the total number of normal tissue voxels. As a result, exact solution of (P ) is computationally intractable. We next develop an algorithm for efficient, approximate solution of (P ). This method uses a simple constraint generation approach that is rooted in the fact that when N is fixed, if we drop the dosevolume constraints, then the resulting problem, although seemingly nonconvex, can be equivalently re-written as a linear program with convex, quadratic constraints. We emphasize here that if the treatment protocol does not include any dose-volume constraints, then our method produces an exact solution to (P ).
An efficient solution method
We first define a sequence of problems P (N ), obtained by fixing N at 1, 2, . . . , N max in (P ). We have,
Note that
Thus, problem (P ) can be solved by first solving the sequence of problems P (N ), for N = 1, 2, . . . , N max , and then choosing an N that yields the best tumor-BE and using the corresponding optimal fluence-map. It is established in Appendix A that P (N ) has an optimal solution for each N ; this implies that (P ) has an optimal solution as well. Now observe that because the objective in P (N ) is increasing inĀu, it is equivalent to maximizingĀu. Thus, we rewrite P (N ) as
Moreover, since A m j u ≥ 0, constraints (28) can be equivalently rewritten as linear constraints wherein the right hand side is obtained by solving a quadratic equation. This yields the equivalent problem
The objective function in this problem is linear; constraints (34) and (37) are linear; constraints (35) are convex, quadratic. Thus, the only remaining computational challenge is posed by the dose-volume constraints (36) . We therefore propose a simple and natural constraint generation approach to surmount this difficulty. In particular, we first solve P (N ) without constraints (36) . Supposeû is an optimal solution to this problem. Then, for each m ∈ M 3 , we find n m − K m voxels that receive the smallest doses among the n m voxels in O m under fluence-mapû. Let subset N m (û, N ) ⊆ N m denote this group of voxels. We then re-solve P (N ) but this time by replacing constraints (36) with tolerance limits on all voxels in the set N m (û, N ). Finally, we note that these tolerance limits, which appeared in definition (11) of functions f j (u, N ), can be equivalently re-written as linear constraints whose right hand side is obtained by solving a quadratic equation. This yields the problem
Problem Q(N ) has a linear objective and only includes linear or convex quadratic constraints and hence it can be solved efficiently. We conclude this section by summarizing our overall algorithm for approximate solution of (P ).
Algorithm for solving (P )
1. For N = 1, 2, . . . , N max , (a) solve problem P (N ) as in (33)- (38) but without dose-volume constraints (36); letû denote a fluence-map that is optimal to this problem, and let N m (û, N ), for each m ∈ M 3 , be the set of voxels that receive the smallest doses among the n m voxels in O m under fluence-mapû;
(b) solve problem Q(N ) to denote its optimal solution by u * (N ) and use its optimal value G * (N ) to approximate the optimal value F * (N ) of problem P (N ) formulated in (20)- (25) as
end the loop over N .
2. UseF (N ) as an approximation to F * (N ) in (26) to obtain an optimal number of fractions N * and use the corresponding optimal fluence-map u * (N * ) in each fraction.
In the next section, we apply this algorithm to ten test cases in head-and-neck and prostate cancer. We perform sensitivity analyses and also quantify the potential benefit of our spatiotemporally integrated approach.
Results
In this section, our computational experiments are designed to illustrate two key points -(i) the qualitative trends in the effect of various problem parameters on the optimal number of fractions and the corresponding optimal tumor-BE are identical to those in our recent spatiotemporally separated model in [48] and also to those in some of the earlier stylized models [3, 4, 14, 15, 16, 17, 19, 32, 35, 42, 58] ; and, crucially, (ii) the spatiotemporally integrated approach achieves a higher tumor-BE than both a model that uses a spatially optimized IMRT fluence-map without optimizing the number of fractions, and our spatiotemporally separated model in [48] . The first of these two points is studied in Section 4.2, and it serves as an indirect validation of our model. The second point, studied in Section 4.3, hints at the potential increase in treatment efficacy, within the LQ framework, that could be obtained by solving our integrated model instead of solving existing stylized models in the literature.
Description of test cases
We first describe the ten test cases that were used in our experiments. Five of these were headand-neck cases and the other five were prostate. All test cases were generated using our in-house phantom creator software PhanC written in MATLAB [50] , and they were identical to the ones we used in [48] . These test cases were three-dimensional and were carefully developed to be representative of clinical scenarios in terms of geometry and size. Specifically, our test cases were similar to those discussed in [24, 41, 46, 47, 51] . All voxels were 3 × 3 × 3 mm 3 . The beamlet resolution was 5 × 5 mm 2 in all cases. All cases used equally spaced coplanar beams (seven for head-and-neck and five for prostate). Computer simulations were performed on a 3.1 GHz iMac desktop with 16 GB RAM using the MATLAB convex optimization toolbox CVX [23] .
Head-and-neck cancer cases
All cases used seven beams and included spinal cord, brainstem, left and right parotids and unspecified normal tissue between these critical organs. The total number of voxels in the head-and-neck target and in the normal tissues, and the total number of beamlets is shown in Table 2 Table 2 : Description of the geometry used in head-and-neck cancer cases. This data is identical to [48] .
The conventional fractionation schedule was assumed to include N conv = 35 fractions. While formulating problem (P ), we included maximum dose constrains for spinal cord, brainstem and unspecified normal tissue. A dose-volume constraint for unspecified normal tissue was also added. Mean dose constrains were used for left and right parotids. The tolerance dose values for various normal tissues were similar to [12, 34, 38, 40] and identical to [48] . These are listed in Table 3 below. All radiobiological parameter values used are listed in Table 4 
Prostate cancer cases
All cases used five beams and included rectum, bladder, left and right femurs and unspecified normal tissue between these critical organs. The total number of voxels in the prostate target and in the normal tissues, and the total number of beamlets is shown in Table 5 below.
case # # of beamlets (k) # of tumor voxels (n) Number of normal tissues voxels  1  938  6180  145545  2  847  7225  326703  3  935  4628  367656  4  930  4956  314544  5 870 4840 269450 Table 5 : Description of the geometry used in prostate cancer cases. This data is identical to [48] .
The conventional fractionation schedule was assumed to include N conv = 45 fractions. In our formulation of problem (P ), we included a maximum dose constraint for unspecified normal tissue, and included dose-volume constraints for all normal tissues. There were no mean dose constraints. The dose-volume constraints for all normal tissues were similar to [12, 34, 38, 40] and identical to [48] . These are listed in Table 6 . All radiobiological parameter values used are listed in Table 7 
Sensitivity to tumor doubling time and to time-lag before proliferation
As in previous work in this area, we found that the optimal number of fractions is smaller for faster growing tumors as characterized by smaller values of the tumor doubling time T double . As an example, the tumor-BE is plotted against N for various values of T double in Figures 1(a) , (b) for our head-and-neck case 1 and prostate case 1. Also, the optimal tumor-BE itself is smaller for faster growing tumors. (b) Figure 1 : Sensitivity of the optimal number of fractions and the optimal tumor-BE to tumor doubling time T double (days) when T lag = 7 days. (a) Head-and-neck case 1; tumor α/β was 10 Gy, and the α/β ratio for all normal tissues was 3 Gy. (b) Prostate case 1; tumor α/β was 6 Gy, and the α/β ratio for all normal tissues was 3 Gy.
Our simulations showed that the tumor-BE can sometimes grow very slowly with N before it starts decreasing. We therefore tracked the smallest number of fractions at which the tumor-BE reached 99% of its optimal value. We denote this number of fractions by N * 99 . The range 1 of this number over all combinations of tumor α/β ratios and normal tissue α/β ratios for our five headand-neck cases is reported in Table 8 . The table shows that the ranges did not change significantly across different cases. The table also shows that for some fixed values of T double , the range of N * 99 is somewhat broad; this is especially true for slower proliferating tumors as characterized by larger T double values. These broad ranges for N * 99 resulted from our choice of a somewhat broad range for α/β values. To further illustrate this point, we present a more detailed set of results for head-and-neck case 1 as an example in Table 9 . These results were obtained for T double = 10 days and T lag = 7 days by fixing the α/β ratios for the unspecified normal tissue, spinal cord and brainstem at 3 Gy and then varying the α/β ratios for the two parotids over the set {3, 4, 5, 6} Gy and the α/β ratios for the tumor over the set {8, 10, 12} Gy. The table shows that for a fixed value of parotid α/β ratio, N * 99 increases with increasing values of tumor α/β. Similarly, for a fixed value of tumor α/β ratio, N * 99 decreases with increasing values of parotid α/β. In summary, N * 99 becomes larger as the relative difference between tumor and parotid α/β grows. In all prostate cases where the tumor α/β ratio was 2 or 3, it was optimal to administer a single fraction for all combinations of α/β ratios for normal tissues as has been noted in the existing 1 Based on our analysis in [48] , 1 + T lag is likely to be a lower bound on the optimal number of fractions; thus, when N * 99 was smaller than 1 + T lag , it was reset to 1 + T lag . Table 9 : Range of N * 99 for head-and-neck case 1 with T double = 10 days, T lag = 7 days, and different combinations of tumor and parotid α/β ratios with α/β for unspecified normal tissue, spinal cord, and brainstem fixed at 3 Gy.
literature on stylized models. The range of N * 99 for all combinations of α/β ratios for normal tissues and α/β = 4, 6 for tumor is shown in Table 10 for our five test cases. The table shows that the ranges did not change significantly across different cases. To shed further light on the somewhat broad range of N * 99 values for some fixed values of T double , we present more detailed results for prostate case 1 as an example in Table 11 . These results were obtained by fixing T double = 30 days and T lag = 7 days, fixing the unspecified normal tissue and femur α/β at 3 Gy, varying the bladder and rectum α/β ratios over the set {3, 4, 5, 6} Gy, and varying the tumor α/β ratio over the set {4, 6} Gy. As in head-and-neck, N * 99 increases with increasing relative difference between tumor and normal tissue α/β. Table 10 : Range of N * 99 for five prostate cases with T lag = 7 days and α/β = 4, 6 for tumor and all combinations of normal tissue α/β ratios.
We also investigated the sensitivity of the optimal number of fractions to T lag . Our experiments confirmed (see Tables 12 and 13 ) that for small values of T double relative to T lag , the optimal number of fractions is equal to 1 + T lag ; for larger value of T double , the optimal number of fractions is not tumor α/β rectum and bladder α/β 4  6  3  8  44  4  8  26  5  8  20  6 8 18 Table 11 : Range of N * 99 for prostate case 1 with T double = 30 days, T lag = 7 days, and different combinations of tumor, rectum and bladder α/β ratios with α/β for unspecified normal tissue and femurs fixed at 3 Gy. sensitive to T lag . As in Tables 8 and 10 , the range of N * 99 did not vary across different test cases; therefore, in Tables 12 and 13 , we simply listed the range of N * 99 over all head-and-neck and prostate cases, respectively, rather than separating them case-by-case. For each T double , T lag combination, the somewhat broad range of N * 99 again resulted from our broad range of α/β values as previously demonstrated in Tables 9 and 11 . Table 13 : Range of N * 99 over five prostate cases for α/β = 4, 6 for tumor over all combinations of normal tissue α/β ratios.
Improvement in tumor-BE

Comparison with conventional IMRT
First, we compare the tumor-BE obtained by our spatiotemporally integrated approach with that from a conventional IMRT optimization model that does not optimize the number of fractions. The number of fractions and the prescription dose were fixed at N hn conv = 35, D hn presc = 70 Gy for head-and-neck cancer, and N pr conv = 45, D pr presc = 81 Gy for prostate cancer similar to [38] . The IMRT optimization model minimized the total squared-deviation of tumor voxel doses from the prescription doses. Maximum dose constraints for spinal cord and brainstem and mean dose constraints for parotids with dose tolerance levels tabulated in Section 4.1.1 were included for headand-neck cases. Maximum dose constraints of 85, 89 and 65 Gy for rectum, bladder, and femurs, respectively were included for the prostate cases similar to [38] . Smoothness constraints were also included in all ten cases.
The resulting model for head-and-neck was as follows:
Suppose u hn is an optimal solution to this problem. Then, its tumor-BE is computed using formula (2) as
conv ). The model for prostate was as follows: , for all voxels j in right femur,
Suppose u pr is an optimal solution to this problem. Then, its tumor-BE is computed using formula (2) as
conv ). The improvements in tumor-BE obtained by our spatiotemporally integrated approach over conventional IMRT are listed in Figures 2(a) and (b) for head-and-neck and prostate, respectively, for T lag = 7 days as an example since the trends in improvements were not sensitive to T lag . Figure 2 (a) for head-and-neck cases shows that the improvement in tumor-BE achieved by our spatiotemporally integrated approach over conventional IMRT first decreases and then increases with increasing values of T double . Specifically, the potential benefit of our integrated approach is likely to be the largest for fast and slowly proliferating head-and-neck tumors. In particular, the most significant benefits are likely to be achieved for fast proliferating tumors. This overall trend is consistent with the fact that the optimal number of fractions obtained by our integrated approach is closest to the conventional value of 35 for moderately proliferating tumors as seen in Table 8 . Figure 2 (b) for prostate cases shows a different trend. For each case, the improvement decreases with increasing values of T double . The magnitude of the improvement itself seems to be bigger than that in head-and-neck. This is because, as seen in Table 10 , the optimal number of fractions is significantly different from the conventional value of 45 for most parameter combinations.
A more detailed analysis of the trends in Figures 2(a) , (b) is provided in Figures 3(a) , (b) for head-and-neck case 1 and prostate case 1, respectively. For head-and-neck, Figure 3(a) shows that, for most values of T double , the spatiotemporally integrated model achieves larger improvements over conventional IMRT for larger values of tumor α/β when all normal tissue α/β ratios are fixed at 3 Gy. This is because the difference between the optimal number of fractions derived from our integrated model and the conventional value of 35 increases for larger values of tumor α/β. For prostate, Figure 3(b) shows that the largest improvement is achieved when tumor α/β is 2 or 3 Gy when all normal tissue α/β ratios are fixed at 3 Gy. This is because, as stated earlier, a single fraction is optimal in those cases and this value is significantly different from the conventional value of 45.
Comparison with a spatiotemporally separated model
Second, we compare the tumor-BE achieved by our spatiotemporally integrated model with that attained by our spatiotemporally separated model in [48] . In that model, the objective was to maximize the biological effect of average tumor dose subject to the same dose constraints on normal tissues as in our formulation (P ). However, there, a spatially optimized IMRT fluence-map as in Section 4.3.1 was assumed to be available as input and fixed a priori ; the number of fractions was then optimized with respect to this fluence-map using a sparing factors approach. This led to a closed-form formula for the average tumor-dose per fraction as a function of the number of fractions. The tumor-BE of this average tumor-dose was then characterized as a quasiconcave function of the number of fractions using formula (2) . This resulted in a simple procedure for finding an optimal number of fractions.
The improvements in tumor-BE obtained by our spatiotemporally integrated approach over the spatiotemporally separated model are plotted in Figures 2(c) and (d) for head-and-neck and prostate, respectively, for T lag = 7 days as an example. The qualitative trend in the improvements shown in Figure 2 (c) for our head-and-neck cases is similar to that in Figure 2 (a). For our prostate cases plotted in Figure 2(d) , the improvement is much less sensitive to T double since the optimal number of fractions obtained by our integrated approach and the separated model is similar in most cases as this number is often 1 or 1 + T lag .
We conclude this section by elaborating on one observation that might seem surprising at first. A comparison of Figures 2(a) and (c) shows that the improvement achieved by our spatiotemporally integrated approach over the spatiotemporally separated approach is sometimes larger than that over conventional IMRT. This seems counterintuitive, because the spatiotemporally separated model uses a conventional, spatially optimized IMRT fluence-map for a conventional number of fractions as input and improves upon it by optimizing the number of fractions. Specifically, the improvement over IMRT should be at least as large as the improvement over the spatiotemporally separated model. This intuition is correct. The apparent contradiction is rooted in the fact that the constraints in our spatiotemporally separated model in [48] were more conservative than in the conventional IMRT model used here. This is because, for reasons explained in Section 2.2.2, the spatiotemporally separated model in [48] also puts an upper bound on the average BED over all normal tissue voxels as in this paper, whereas conventional IMRT uses an upper bound on the average dose over all voxels.
Discussion
We built a spatiotemporally integrated model for the optimal fractionation problem using the LQ framework. Decision variables in this formulation correspond to the number of fractions as well as the fluence-map. We proposed an efficient, convex programming algorithm for approximate solution of this problem. Computer simulations on test cases suggest that this approach could potentially increase the tumor-BE within the LQ framework as compared to a conventional IMRT optimization model that does not optimize the number of fractions and also as compared to a recently proposed model that separates the spatial and the temporal components of the problem. Our sensitivity analyses provided insights into the effect of various model parameters on the resulting solutions.
Our algorithm tackles dose-volume constraints in a simple, natural, and efficient manner while preserving convexity. It should also be possible to use other existing methods to handle dosevolume constraints although we did not pursue this direction here as it is not the main focus of this paper (see, for example, the literature review and methods in [46] ). We believe that our qualitative observations in this paper will hold for such alternative formulations.
Many alternative fractionation schedules have been tested clinically. Examples include once daily treatment but only over weekdays and twice daily treatment only over weekdays. Our formulation (P ) can be easily modified to accommodate such fractionation strategies by redefining function τ (N ) in Equation (1) as described in our previous work in [48] .
Finally, one limitation of our formulation is the assumption that an identical fluence-map is used in every session; that is, it only considers equal-dosage fractionation. This is consistent with prevalent practice. However, it has been recently suggested in [49, 59 ] that this may not be optimal. It would be interesting to formulate and solve a more general version of our spatiotemporally integrated model that allows for the fluence-map to change across sessions. The number of variables in such a model will be an order of magnitude larger than that in our model here. We therefore defer the development of efficient algorithms for its approximate solution to future research.
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A Proof of existence of an optimal solution to P (N )
Without loss of generality, we assume that for every normal tissue m ∈ M, every row of the dose deposition matrix A m has at least one strictly positive entry. For if not, then the normal tissue voxel corresponding to a zero row in A m can be removed from further consideration as radiation does not reach that voxel. Also without loss of generality, we assume that there exists either a serial normal tissue m ∈ M 1 or a parallel normal tissue m ∈ M 2 with the property that every column of its dose deposition matrix A m includes at least one strictly positive entry. For if there exists a column c without any strictly positive entries, then it turns out that the cth component of u, denoted u c , can be increased arbitrarily without damaging any normal tissue. This assumption is met in practice for example when maximum dose constraints are included on the unspecified The average percentage improvement achieved by our spatiotemporally integrated approach over: (a) IMRT for headand-neck, (b) IMRT for prostate, (c) spatiotemporally separated model in [48] for head-and-neck, and (d) spatiotemporally separated model in [48] . These numbers are for T lag = 7 days and averaged over all combinations of tumor and normal tissue α/β ratios. normal tissue because each radiation beamlet must pass through at least some unspecified normal tissue and hence the corresponding row of A m will have a strictly positive entry.
Lemma A.1. Problem P (N ) has an optimal solution for each N ≥ 1.
Proof. For every m ∈ M 3 , dose-volume constraints (23) imply that, the BED for at least L m n m − K m and at most n m voxels in O m should be less than BED W m ways to express our dose-volume constraints. Let w w 1 , w 2 , . . . , w |M 3 | .
We create W subproblems from P (N ), each representing one of these W ways of expression. 
An optimal solution to P (N ) can be recovered by choosing the best among optimal solutions to these subproblems. Thus, we prove that each of the above W problems has an optimal solution. Let U ( w; N ) ⊂ k denote the set of feasible fluence-map vectors u. This set is nonempty because the trivial fluence-map u = 0 is feasible to P ( w; N ). Suppose a serial normal tissue m ∈ M 1 has a strictly positive entry in each column of its dose deposition matrix A m (if instead a parallel normal tissue possesses this property, then the proof can be modified easily). For any l = 1, 2, . . . , k, let I l denote the set of rows of A m in which the entry in the lth column is strictly positive. For all i ∈ I l , we denote the corresponding positive entries of A m by A m i,l . Since all entries in A m are nonnegative, the maximum dose constraint on this normal tissue implies that A m i,l u l ≤ BED . Thus, the feasible region is bounded. It is also closed as all constraint functions are continuous. Moreover, the objective function in P ( w; N ) is also continuous. Thus, P ( w; N ) has an optimal solution as claimed.
